

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/567,299	02/06/2006	Heribert Hellstern	ON/4-33308A	6687
1095 NOVARTIS	90 10/12/2007		EXAMINER	
CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3			LUKTON, DAVID	
EAST HANOVER, NJ 07936-1080			ART UNIT	PAPER NUMBER
			1654	
	. ′		MAIL DATE	DELIVERY MODE
			10/12/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•					
•	Application No.	Applicant(s)			
	10/567,299	HELLSTERN ET AL.			
Office Action Summary	Examiner	Art Unit			
	David Lukton	1654			
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with the	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perior - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the main earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be to will apply and will expire SIX (6) MONTHS froute, cause the application to become ABANDON	ON. imely filed m the mailing date of this communication. IED (35 U.S.C. § 133).			
Status	•				
1) Responsive to communication(s) filed on 10	<u>August 2007</u> .				
2a) ☐ This action is FINAL . 2b) ☑ Th	This action is FINAL . 2b)⊠ This action is non-final.				
3) Since this application is in condition for allow					
closed in accordance with the practice under	r Ex parte Quayle, 1935 C.D. 11, 4	453 O.G. 213.			
Disposition of Claims					
4) Claim(s) <u>1-6</u> is/are pending in the application	n. ·				
4a) Of the above claim(s) <u>3-6</u> is/are withdraw	n from consideration.				
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1 and 2</u> is/are rejected.					
7) Claim(s) is/are objected to.	Var alastian resuitant 1				
8) Claim(s)are subject to restriction and	voi election requirement.				
Application Papers					
9) The specification is objected to by the Exami					
10) The drawing(s) filed on is/are: a) □ ad					
Applicant may not request that any objection to the		···			
. Replacement drawing sheet(s) including the corre		•			
11) The oath or declaration is objected to by the	Examiner, Note the attached Offic	e action of form PTO-152.			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreignal All b) Some * c) None of: 1. Certified copies of the priority docume 	,	a)-(d) or (f).			
2. Certified copies of the priority docume		tion No			
3. Copies of the certified copies of the pr	• • •				
application from the International Bure	eau (PCT Rule 17.2(a)).				
* See the attached detailed Office action for a li	st of the certified copies not receive	ved.			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summar	ry (PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail I 5) Notice of Informal	Date			
Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	6) Other:	r atent Application			

Applicants' election of Group 1 is acknowledged, as is the elected specie. Claims 1-2 are examined in this Office action; claims 3-6 are withdrawn.

♦

The following is a quotation of 35 USC. §103 which forms the basis for all obviousness rejections set forth in the Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) and (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made, absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103.

Claims 1-2 are rejected under 35 U.S.C. §103 as being unpatentable over Bruns (*Eur J. Endocrinol* **146**, 707, 2002).

Bruns discloses the elected specie. Bruns does not provide a synthetic method

The claims are drawn to methods of producing a cyclic hexapeptide. A cyclic hexapeptide can be represented as follows, where each of A_1 , A_2 (etc.) represents an amino

acid residue:

$$A_{6}$$

$$A_{1}$$

$$A_{2}$$

$$A_{3}$$

$$A_{4}$$

For a cyclic hexapeptide, there are six peptides which, upon cyclization, will yield the target compound. They are the following:

$$A_1$$
- A_2 - A_3 - A_4 - A_5 - A_6

$$A_2$$
- A_3 - A_4 - A_5 - A_6 - A_1

$$A_3-A_4-A_5-A_6-A_1-A_2$$

$$A_4-A_5-A_6-A_1-A_2-A_3$$

$$A_5$$
- A_6 - A_1 - A_2 - A_3 - A_4

$$A_6-A_1-A_2-A_3-A_4-A_5$$

Via instant claim 1, applicants have chosen three of the six possibilities. Given that there are only six possibilities to begin with, it is difficult to argue that any of them is unobvious. Perhaps it will turn out that one of the six processes produces better yields or fewer side

reactions. But all six are obvious.

4

Claims 1-2 are rejected under 35 U.S.C. §103 as being unpatentable over Albert (US 2005/0014686).

Albert discloses the elected specie. Also disclosed is a method of obtaining the compound by cyclizing one of the six possible peptides. As it happens, what is disclosed is a method of cyclizing the peptide in which Phe is the N-terminal amino acid, and O-benzyltyrosine is the C-terminal. The synthetic peptide chemist of ordinary skill would regard this particular choice as arbitrary; the chemist would expect, a priori, about equal rates of success for the six (linear) peptide precursors.

DAVID LUKTON, PH.D. PRIMARY EXAMINER

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached at (571)272-0562. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.